Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation

• Published in: The Journal of nutritional biochemistry 2023-02, Vol.112, p.109186-109186, Article 109186
• Main Authors: Zhang, Han, Chen, Hui, Yin, Shutao, Fan, Lihong, Jin, Caiwei, Zhao, Chong, Hu, Hongbo
• Format: Article
• Language: English
• Subjects: B7-H1 Antigen - metabolism; Cell Line, Tumor; Docosahexaenoic acid; Docosahexaenoic Acids - pharmacology; Docosahexaenoic Acids - therapeutic use; Humans; Immune suppression; Neoplasms - drug therapy; Non-small cell lung cancer; PD-L1; Programmed Cell Death 1 Receptor; Proteasome Endopeptidase Complex; Ubiquitin; Ubiquitin-proteasome degradation
• ISSN: 0955-2863; 1873-4847
• DOI: 10.1016/j.jnutbio.2022.109186

PD-L1 interacts with its receptor PD-1 on T cells to negatively regulate T cell function, leading to cancer cell immune escape from the immune surveillance. Therefore, targeting PD-L1 is considered to be an attractive approach for cancer immunotherapy. In this study, we demonstrated for the first time that ω-3 polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) reduced the expression of PD-L1 in cancer cells both in vitro and in vivo. Promotion of PD-L1 ubiquitin-proteasome degradation by DHA resulted in a decrease of PD-L1 expression, leading to reduction of PD-L1 and PD-1 interaction, and reversing PD-L1-mediated immune suppression, which in turn contributed to the inhibitory effect on tumor growth. Furtherly, DHA significantly reduced fatty acid synthase (FASN) expression in cancer cells, which inhibited the palmitoyltransferases DHHC5, promoting the CSN5-dependent PD-L1 degradation. Our present finding uncovered a novel mechanism involved in the anti-cancer activity of DHA, and implicated that DHA holds promising potential to be developed as a novel immune-enhancer for cancer treatment and prevention.